PRECLINICAL EVALUATION OF A NITRIC OXIDE-RELEASING PRODRUG AS A TREATMENT FOR CHRONIC MYCOBACTERIUM ABSCESSUS INFECTIONS

Mark H. Schoenfisch, PhD Co-founder & CSO Vast Therapeutics, Inc.​

Presentation at the World Bronchiectasis & NTM Conference | 2022-07-01